Top Suppliers:I want be here
Related CAS#:
71939-50-9 81496-82-4
123930-80-3 131175-87-6
81496-81-3 176774-98-4
75887-51-3 850407-45-3
75887-54-6 198817-95-7

71939-50-9

71939-50-9 structure
71939-50-9 structure
  • Name: Dihydroartemisinin
  • Chemical Name: Dihydroartemisinin
  • CAS Number: 71939-50-9
  • Molecular Formula: C15H24O5
  • Molecular Weight: 284.348
  • Catalog: API Antiparasitic drug Antimalarial
  • Create Date: 2018-02-18 08:00:00
  • Modify Date: 2024-01-02 19:56:58
  • Dihydroartemisinin is a potent anti-malaria agent.
Name Dihydroartemisinin
Synonyms Dihydroartemisinin
Dihydroartemisin
3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-ol, decahydro-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,10S,12R,12aR)-
Cotecxin
Dihydroginghaosu
(1S,4S,7R,8S,11R,12S,13R)-1,7,11-Trimethyl-3,5,14,15-tetraoxatetracyclo[10.3.1.0.0]hexadecan-6-ol
MFCD00274495
(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0.0]hexadecan-10-ol
Alaxin
[3H]-(10R/S)-Artenimol
Salaxin
artenimol
3,12-Epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, decahydro-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,10S,12R,12aR)-
(3R,5aS,6R,8aS,9R,12S,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-ol
(3R,5aS,6R,8aS,9R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-ol
dihyhydroartemisinin
DHQHS 2
(5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-ol
3,12-Methano-5aH,7H-1,2,5-trioxepino[3,4-j][2]benzopyran-7-ol, octahydro-3,8,11-trimethyl-, (3S,5aS,8R,8aS,11R,12S,12aR)-
Dihydroarteminisin
dihydroquinghaosu
(3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-ol
Cotexin
Dihydroqinghaosu
Description Dihydroartemisinin is a potent anti-malaria agent.
Related Catalog
Target

RelA

Autophagy
In Vitro Dihydroartemisinin (DHA) is an antimalarial agent. Dihydroartemisinin treatment effectively up-regulates the cytosolic RelA/p65 protein level and down-regulates the nuclear RelA/p65 protein level. Dihydroartemisinin blocks the nuclear translocation of RelA/p65 from the cytosol rather than suppressing RelA/p65 protein synthesis. Dihydroartemisinin induces autophagy in RPMI 8226 cells. Dihydroartemisinin suppresses NF-κB activation in RPMI 8226 cells. The NF-κB Dihydroartemisinin -binding activity is examined by EMSA assay. RPMI 8226 cells are exposed to various concentrations of Dihydroartemisinin (10, 20 and 40 μM) for 12 h, and TNF-α is introduced as a positive control for NF-κB activation. Dihydroartemisinin suppresses NF-κB activation in a dose-dependent manner in contrast with TNF-α[1]. Dihydroartemisinin (DHA) can enhance the anti-tumor effect of photodynamic therapy (PDT) on esophageal cancer cells, and cell viability is investigated using the MTT assay. Eca109 and Ec9706 cells are treated with Dihydroartemisinin (80 μM), PDT (25 and 20 J/cm2, respectively) or their combination. Single treatment with Dihydroartemisinin or PDT causes a 37±5% or 34±6% reduction in viability in Eca109 cells and a 33±7% or 34±6% reduction in Ec9706 cells, respectively. However, when PDT is combined with Dihydroartemisinin, the cell viability is reduced 59±6% or 61±7% in the cell lines, respectively[2].
In Vivo Single oral doses of Dihydroartemisinin (at 200, 300, 400 or 600 mg/kg), given once on each of day 6-8 post-infection, reduce total-worm burdens by 69.2%-90.6% and female-worm burdens by 62.2%-92.2%, depending on dosage in the first experiment. Similar treatments given on day 34-36 post-infection reduce total-worm burdens by 73.9%-85.5% and female-worm burdens by 83.8%-95.3%[3].
Kinase Assay To determine NF-κB Dihydroartemisinin-binding activity, an electrophoretic mobility shift assay (EMSA) is performed. Nuclear extracts are prepared and incubated with 32P-end-labeled 45-mer double-stranded oligonucleotide (15 μg protein with 16 fmol DNA) from the HIV long terminal repeat, 5′-TTGTTACAAGGGACTTTCCGCTG GGGACTTTCCAGGGAGGCGTGG-3′ (boldface indicates NF-κB binding sites), for 30 min at 37 °C. The Dihydroartemisinin-protein complex formed is separated from free oligonucleotide on 6.6% native polyacrylamide gels. A double-stranded mutated oligonucleotide, 5′-TTGTTACAA CTCACTTTCCGCTGCTCACTTTCCAGGGAGGCGTGG-3′, is used to examine binding specificity of NF-κB to the DNA. The binding specificity is also examined by competition with the unlabeled oligonucleotide. Preimmune serum (PIS) is included as a negative control. The dried gels are visualized with a Storm 820, and radioactive bands are quantified using Imagequant software[1].
Cell Assay Eca109 (4×103 cells/well) and Ec9706 (5×103 cells/well) cells are grown in 96-well plates and cultured overnight to allow for cell attachment. Eca109 and Ec9706 cells are treated with Dihydroartemisinin (80 μM), PDT (25 and 20 J/cm2, respectively) or their combination. After incubation for 24h, MTT (20 μL) is added to each well and incubated for 4 h at 37°C. Formazan crystals are dissolved in 150 μL of DMSO for 10 min with shaking. The absorbance is measured at 490 nm on a plate reader, and the experiment is repeated three times[2].
Animal Admin Mice[3] Mice of the Kunming strain, each weighing 20-24 g, are used. In the first experiment, design to investigate the effect of multiple doses of Dihydroartemisinin on the schistosomula and adult worms of S. japonicum, mice are given three daily doses, of 200, 300, 400 or 600 mg Dihydroartemisinin/kg (in dose volumes of 25 mL/kg), on days 6-8 or 34-36 post-infection, respectively. An additional group of mice, infected but not given the drug, serve as a control.
References

[1]. Hu W, et al. Dihydroartemisinin induces autophagy by suppressing NF-κB activation. Cancer Lett. 2014 Feb 28;343(2):239-48.

[2]. Li YJ, et al. Dihydroartemisinin accentuates the anti-tumor effects of photodynamic therapy via inactivation of NF-κB in Eca109 and Ec9706 esophageal cancer cells. Cell Physiol Biochem. 2014;33(5):1527-36.

[3]. Li HJ, et al. Dihydroartemisinin-praziquantel combinations and multiple doses of dihydroartemisinin in the treatment of Schistosoma japonicum in experimentally infected mice. Ann Trop Med Parasitol. 2011 Jun;105(4):329-33.
Density 1.3±0.1 g/cm3
Boiling Point 375.6±42.0 °C at 760 mmHg
Melting Point 144-149ºC
Molecular Formula C15H24O5
Molecular Weight 284.348
Flash Point 181.0±27.9 °C
Exact Mass 284.162384
PSA 57.15000
LogP 2.27
Vapour Pressure 0.0±1.9 mmHg at 25°C
Index of Refraction 1.543
Storage condition 2-8°C
Hazard Codes T+
Safety Phrases 22-24/25
RIDADR NONH for all modes of transport
WGK Germany 2
63968-64-9 structure

63968-64-9

~98%

71939-50-9 structure

71939-50-9
Literature: Avery, Mitchell A.; Mehrotra, Sanjiv; Johnson, Theresa L.; Bonk, Jason D.; Vroman, Jeffrey A.; Miller, Robert Journal of Medicinal Chemistry, 1996 , vol. 39, # 21 p. 4149 - 4155
63968-64-9 structure

63968-64-9

~%

71939-50-9 structure

71939-50-9

81496-81-3 structure

81496-81-3
Literature: Organic Process Research and Development, , vol. 16, # 5 p. 1039 - 1042
81496-81-3 structure

81496-81-3

~%

71939-50-9 structure

71939-50-9
Literature: Molecules, , vol. 15, # 12 p. 8747 - 8768

Chemsrc provides CAS#:71939-50-9 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 71939-50-9 | Chemsrc address: https://www.chemsrc.com/en/baike/831482.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved